All In Biotech

Drug Trial Radar · NCT05819398

Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

Randomised, Double-blind, Placebo-controlled, Phase IIb/Phase III Study to Evaluate the Efficacy and Safety of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa. Lunsayil 1.

Last checked: Nov 20, 2026Latest source record: Nov 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 209 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

209

Actual

Start

Apr 17, 2023

Primary completion

Aug 1, 2024

Study completion Mar 31, 2025

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Apr 19, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is open to adults with moderate to severe hidradenitis suppurativa (HS). The purpose of this study is to find out whether a medicine called spesolimab helps people with HS. People who have previously taken specific medicines such as immunosuppressive biologics other than Tumor necrosis factor (TNF) inhibitors cannot take part. This study has 2 parts. In Part 1, participants are divided into 4 groups of almost equal size. 3 groups get different doses of spesolimab, 1 group gets placebo. All participants get injections into a vein or under the skin. Placebo injections look like spesolimab injections, but do not contain any medicine. Every participant has an equal chance of being in each group. In the beginning, participants get the study medicine every week and later every 2 weeks. After 4 months, participants in the placebo group switch to spesolimab treatment. In Part 2, participants are divided into 2 groups. One group gets a suitable dose of spesolimab that was found in Part 1 of the study. The other group gets placebo. After 4 months, participants in the placebo group switch to spesolimab treatment. Participants join only one of the two parts. They are in the study for about 1 year. During this time, they visit the study site in the beginning every week and later every 2 weeks. Some of the visits can be done at the participant's home instead of the study site. The doctors regularly check participants' HS symptoms. The results are compared between the groups to see whether spesolimab works. The doctors also regularly check participants' general health and take note of any unwanted effects.

Conditions

  • Hidradenitis Suppurativa

Interventions

  • Spesolimab i.v.Drug

    Weekly dose of spesolimab via i.v. for 4 weeks.

  • Spesolimab s.c.Drug

    Weekly s.c. dose of spesolimab for 4 weeks (3 weeks for Placebo), and maintenance s.c. dose of spesolimab every two weeks until the end of the treatment.

  • Placebo matching Spesolimab i.v.Drug

    Weekly dose of placebo via i.v. for 4 weeks.

  • Placebo matching Spesolimab s.c.Drug

    Weekly s.c. dose of placebo for 4 weeks, and once every 2 weeks for the following 7 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1 - Percent Change From Baseline in Draining Fistula/Tunnel (dT) Count at Week 8Time frame: The MMRM model incorporates dT count from baseline (Week 0), Week 2, Week 4, Week 6 and Week 8. The data represent the Least Squares Means at Week 8.

Locations

162 sites in 35 countries. Site status is shown where the registry gives one.

  • First OC Dermatology

    Fountain Valley, California

  • Dermatology Research Associates

    Los Angeles, California

  • Integrative Skin Science and Research-Sacramento-69402

    Sacramento, California

  • Clinical Trials Research Institute

    Thousand Oaks, California

  • Ziaderm Research

    North Miami Beach, Florida

  • ForCare Clinical Research, Inc.

    Tampa, Florida

  • Olympian Clinical Research-Tampa-69560

    Tampa, Florida

  • Dawes Fretzin Clinical Research Group, LLC-Indianapolis -68995

    Indianapolis, Indiana

  • Skin Sciences, PLLC

    Louisville, Kentucky

  • University of Michigan Health System

    Ann Arbor, Michigan

  • Oakland Hills Dermatology, PC

    Auburn Hills, Michigan

  • Skin Specialists, P.C.

    Omaha, Nebraska

  • AXIS Clinicals

    Fargo, North Dakota

  • Unity Clinical Research

    Oklahoma City, Oklahoma

  • University of Pennsylvania

    Philadelphia, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Palmetto Clinical Trial Services

    Greenville, South Carolina

  • Center for Clinical Studies-Houston-58806

    Houston, Texas

  • Progressive Clinical Research

    San Antonio, Texas

  • STAT Research

    CABA, Argentina

  • Hospital Italiano de Buenos Aires

    CABA, Argentina

  • Hospital Alemán

    Capital Federal, Argentina

  • Centro de Investigaciones Medicas Mar del Plata

    Mar del Plata, Argentina

  • Instituto de Especialidades de la Salud Rosario

    Rosario, Argentina

  • Sanatorio 9 de Julio S.A.

    San Miguel de Tucumán, Argentina

  • Holdsworth House Medical Practice

    Sydney, New South Wales, Australia

  • Westmead Hospital

    Westmead, New South Wales, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

  • AKH - Medical University of Vienna

    Vienna, Austria

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium

  • Centre Hospitalier Universitaire de Liège

    Liège, Belgium

  • Medical Center "Kordis"

    Pleven, Bulgaria

  • ASMC-IPSMC-skin and Veneral Diseases

    Sofia, Bulgaria

  • Diagnostic Consultative Center Alexandrovska

    Sofia, Bulgaria

  • DCC "Fokus-5-LZIP" OOD

    Sofia, Bulgaria

  • Medical Military Academy MHAT Sofia

    Sofia, Bulgaria

  • MHAT Prof Stoyan Kirkovich AD

    Stara Zagora, Bulgaria

  • Alberta DermaSurgery Centre

    Edmonton, Alberta, Canada

  • SimcoDerm Medical and Surgical Dermatology Centre

    Barrie, Ontario, Canada

  • Guelph Dermatology Research

    Guelph, Ontario, Canada

Showing 40 of 162 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.